23andMe Investor Presentation Deck
We Have Generated a Research and Development
Pipeline Covering Multiple Therapeutic Areas
Immuno-oncology
GSK'608¹
(CD96)
EARLY-STAGE THERAPEUTIC AREAS
(multiple programs in each area)
Immuno-oncology
Immunology
23ME'610
(CD200R1)
Cardiovascular/ Metabolic
Neurology
Discovery
Preclinical
Phase 1
GSK
23andMe
50+
programs²
1. GSK is solely responsible for the development of GSK6097608 (GSK'608) in later-stage clinical trials. Subject to its successful commercialization, 23andMe is eligible to earn tiered
worldwide royalties up to the low double digits.
2. The 50+ programs in the combined therapeutic areas include 100% owned and royalty interest targets as well as those in collaborations. The majority of the programs are in
collaboration with GSK. Note: As of March 31, 2022
Phase 2
Copyright © 2022 23and Me, Inc.
Next Milestone
Phase 2 Data
Phase 1 Data
23andMe
33View entire presentation